The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Par Pharmaceutical Companies Inc  (PRX) Trade Now »     Rate PRX  -  Discuss PRX  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
100.0%
Top:
100.0%
Rate PRX:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

PRX: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

From the Blogosphere

Generic Drug Makers

Here’s another terrific post by Pharmboy, this time discussing Generic Drug Makers. - Ilene

Generic Drug Makers

Variety of Pills

<script type="text/javascript" src="http://cdn.pis.picapp.com/IamProd/PicAppPIS/JavaScript/PisV4.js"></script>

Courtesy of Pharmboy

Coming to the end of a good year, and good riddance for some!  Whilst the market has been irrational for some time, it is not about what we think but rather about what others that have money think.  I have my notions, and here are a few companies that may do well in the New Year with a passed health care reform bill.

<>I really like the generic market ri...
By  Philip Davis   (+0.00%)  11/10/09 Comment


Notable Analyst Rating Changes 10/15: JPM, PCG, NVLS, PRX Upgrade; BJS, BHI, SCHW, AZ, TRV, LAZ Downgrade
UPGRADES:Fox-Pitt upgrades JPMorgan Chase (NYSE: JPM) from In-line to Outperform. Price target increased to $55 from $38. UBS upgrades PG&E Corp (NYSE: PCG) from Neutral to Buy.Citi upgrades Novellus (Nasdaq: NVLS) from Hold to Buy. Price target increased from $19.50 to $27. Barclays is upgrading Per Pharmaceuticals (NYSE: PRX) to Overweight from Equal Weight with a $30 target (prev. $18). Click Here for more color.For daily real-time Upgrades go to http://www.streetinsider.com/UpgradesDOWNGRADES:Citi downgrades BJ Services (NYSE: BJS) from Hold to Sell. Price target lowered from $16 to $1...
By  Street Insider   (+0.33%  risk: moderate)  10/15/09 Comment


Mylan: Generic Drugmaker with a Strong Portfolio
<>Mylan Pharmaceuticals (MYL) keeps coming up on my radar so I would like to take the time to analyze the stock and give some recommendations on it. Mylan is approaching its 52 week high so is it a buy or not? In October 2008, they reached a 52 week low of 5.75 and today is trading at 14.88. So that old adage of Buy Low-Sell High is coming into play. In these economic times many rules of trading are finding exceptions to that rule. Mylan's Financial picture can be found on Google Finance here. I see a good exception to Mylan's future, and see the company's stock rising based on FDA approvals ...
By  trackseekingalpha   (-13.40%  risk: aggressive)  08/28/09 Comment


Notable Analyst Rating Changes 8/19: PRX, ANN, BPOP, AXL, JOYG Upgraded; AA, ANF, TOL, DHI, LUV Downgraded
UPGRADES:Goldman Sachs, Buckingham and Caris upgrade Par Pharma (NYSE: PRX) to Neutral, Accumulate and Buy, respectively. UBS upgrades Ann Taylor (NYSE: ANN) to Buy. Piper Jaffray is also out reiterating its Overweight rating. Click here for the full report. Keefe, Bruyette & Woods upgrades Popular, Inc. (Nasdaq: BPOP) from Market Perform to Outperform. Price target $3.50. Here is more color on the upgrade.Credit Suisse upgrades American Axle (NYSE: AXL) from Neutral to Outperform. Macquarie upgrades Joy Global (Nasdaq: JOYG) from Neutral to Outperform. Price target increased from $36 to $4...
By  Street Insider   (+0.33%  risk: moderate)  08/19/09 Comment


Big Pharma Goes Generic
Mikerun
73%
Sanofi-Aventis (SNY) is now the 11th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVentures which will specialize in bio-generics.

Elsewhere in the industry, India-based Ranbaxy (RANBAXY.NS) lost about 20% of its market value today on word the FDA would not review new generic drug prod...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/08/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.44% 381
2 Gerald Greene 18.14 +71.24% 211
3 stockmarketfunding.com 17.66 +25.60% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment
INTC Intel Corp
AMD Advanced Micro Devices Inc
BAC Bank of America Corp
SIRI Sirius Satellite Radio Inc
NVDA NVIDIA Corp
PFE Pfizer Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on PRX

Visit streetinsider.com


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Par Pharmaceutical Companies Inc - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch